CCM
ANIP icon

Cribstone Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Cribstone Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-40
Closed -$3K – 773
2018
Q2 		$3K Buy
+40
New +$2.5K ﹤0.01% 679

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Cribstone Capital Management's ANIP Position: Q3 2018 in Review

Cribstone Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q3 2018, closing a stake of 40 shares — an estimated $3K sold.

Cribstone Capital Management first reported a position in ANIP in Q2 2018 and held it in 1 quarter. The position peaked at $3K in Q2 2018. 173 funds tracked by Wall St. Rank hold ANIP as of Q3 2018.

  • Cribstone Capital Management reported no remaining ANI Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Cribstone Capital Management sold 40 ANI Pharmaceuticals shares in Q3 2018, an estimated $3K.
  • Cribstone Capital Management first reported a position in ANI Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Cribstone Capital Management's ANI Pharmaceuticals position peaked at $3K in Q2 2018.
  • 173 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2018.

Based on Cribstone Capital Management's 13F filing for Q3 2018, filed 25 Oct 2018.